Last reviewed · How we verify
MK0831
MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment.
MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | MK0831 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CCR4 antagonist |
| Target | CCR4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CCR4 is highly expressed on regulatory T cells (Tregs) and activated effector T cells. By blocking CCR4, MK0831 depletes Tregs from tumors and enhances anti-tumor immune responses. This mechanism aims to shift the immune balance toward anti-tumor immunity, potentially enhancing checkpoint inhibitor efficacy.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Lymphopenia
- Infections
- Fatigue
- Nausea
Key clinical trials
- A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (PHASE1)
- Pediatric Expanded Access Program-Oral Solution (0831-908) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0831 CI brief — competitive landscape report
- MK0831 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI